Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The High affinity immunoglobulin epsilon receptor subunit alpha (FcεRIα) is a transmembrane protein that serves as the ligand-binding subunit of the high-affinity IgE receptor complex (UniProt P12319). It is predominantly expressed on mast cells and basophils, but also on professional antigen-presenting cells such as oral Langerhans cells (OLCs) (Allam et al., 2003, J Allergy Clin Immunol). In the oral mucosa, FcεRIα plays a pivotal role in capturing aeroallergens like Timothy grass pollen, cat dander, and house dust mites, facilitating their processing and presentation to the immune system (Novak et al., 2004, J Allergy Clin Immunol). This interaction is a cornerstone of the allergic response, leading to the release of pro-inflammatory mediators upon allergen cross-linking. Conversely, in the context of sublingual immunotherapy (SLIT), the receptor's activity on OLCs is essential for inducing mucosal tolerance and shifting the immune response from a Th2 to a Th1/Treg profile (Allam et al., 2008, Allergy). Drugs like Omalizumab target this pathway by sequestering free IgE, thereby preventing its binding to FcεRIα and downregulating the receptor's expression on cell surfaces (PubChem CID 16124778). By modulating the activity of FcεRIα on OLCs, clinicians can influence the success of sublingual immunotherapy (SLIT), which aims to induce immune tolerance rather than inflammation. Consequently, FcεRIα serves as both a critical mediator of allergic pathology and a strategic target for biological therapies designed to interrupt the IgE-mediated signaling cascade.
Anti-IgE monoclonal antibodies bind to the Cε3 domain of circulating IgE, preventing its interaction with the FcεRIα subunit on the surface of immune cells, which leads to a reduction in receptor density and inhibition of allergen-induced activation (PubChem CID 16124778).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High affinity immunoglobulin epsilon receptor subunit alpha (FcεRIα) (FCER1A).